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Abstract: Recent evidence has indicated that active and passive cigarette smoking are 
associated,  in  a  dose-dependent  manner,  with  dysfunction  of  normal  endothelial 
physiology. Tobacco smoke (TS) may predispose individuals to atherogenic and thrombotic 
problems,  significantly  increasing  the  risk  for  ischemic  manifestations  such  as  acute 
coronary syndrome and stroke. Despite the strong evidence for an association between 
smoking and vascular impairment, the impact of TS exposure on the blood-brain barrier 
(BBB) has only been marginally addressed. This is a major problem given that the BBB is 
crucial in the maintenance of brain homeostasis. Recent data have also shown that chronic 
smokers have a higher incidence of small vessel ischemic disease (SVID), a pathological 
condition characterized by leaky brain microvessels and loss of BBB integrity. In the brain 
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TS  increases  the  risk  of  silent  cerebral  infarction  (SCI)  and  stroke  owing  to  the   
pro-coagulant and atherogenic effects of smoking. In this article we provide a detailed 
review  and  analysis  of  current  knowledge  of  the  pathophysiology  of  tobacco  smoke 
toxicity at the cerebrovascular levels. We also discuss the potential toxicity of recently 
marketed “potential-reduced exposure products”. 
Keywords:  tobacco  smoke;  alternative;  blood-brain  barrier;  central  nervous  system; 
inflammation; endothelial cells; white blood cells 
 
1. Introduction 
A great deal is known about the pathophysiologic and clinical effects of tobacco smoke exposure. 
Tobacco  smoke  exposure  is  responsible  for  a  large  portion  of  the  preventable  deaths  worldwide. 
Knowledge of its impact on vascular health, particularly related to cardiac disease, is well established. 
Less  well  described  are  the  mechanisms  of  tobacco  smoke  induced  vascular  damage  in  the 
cerebrovascular system, particularly as they apply to the blood brain barrier.   
2. Tobacco Smoke Induces Oxidative Injury to the Cerebrovascular System 
Oxidative stress is induced by reactive oxygen species (ROS) which are either free oxigen radicals 
or  reactive  anions  containing  oxygen  atoms.  These  highly  reactive  species  can  then  interact  with 
molecules containing oxygen atoms and propagate the production of other free radicals. Accumulation 
of ROS is the result of one of these three factors: (1) an increase in oxidant generation, (2) a decrease 
in antioxidant protection (e.g., shortage of ascorbic acid,
 α-tocopherol, Coenzyme Q10
 ) [1-4], or (3) a 
failure to repair oxidative damage. Under normal conditions, ROS are cleared by the intracellular 
action of superoxide dismutase (SOD), catalase, glutathione (GSH) peroxidase [5] or (extracellular) 
antioxidant vitamins such as ascorbic acid (vitamin C),
 and α-tocopherol (vitamin E).   
Unfortunately tobacco
 smoke contains very high levels of superoxide and other reactive oxygen 
species  (such  as  hydroxyl  radical,  hydrogen  peroxide,  and  peroxynitrite)  derived  from  cigarette 
combustion.  Therefore,
 the  vascular  adverse  effects  of
  smoking  can  be  the  result  of  endothelial 
exposure to ROS (Figure 1) [6-11]. Damage to cells occurs as a result of ROS-induced alterations of 
macromolecules  [12]. These includes lipoperoxidation of polyunsaturated fatty acids in membrane 
lipids,  protein  oxidation,  DNA  strand  breakage  [13-16],  RNA  oxidation  [17],  mitochondrial 
depolarization and apoptosis. Mutations of the nuclear protein p53 which may lead to apoptosis are 
also  associated  to  tobacco  smoke  toxicity.  Specifically  to  direct  DNA  damage  from  carcinogens 
contained  in  cigarette  smoke  [18-20].  In  vivo  and  in  vitro  studies  have  shown  that  antioxidant 
supplementation prevents, to some extent, the oxidative damage and inflammation induced by cigarette 
smoke  exposure  [21-23],  thus  strongly  supporting  the  hypothesis  of  a  ROS-mediated  toxicity  of 
tobacco  smoke  exposure.  Additionally,  oxidative  stress  and  ROS  have  been  implicated  in  disease   
states, such as Alzheimer’s disease [24], Parkinson’s disease [25], various cancers [26], and aging   
processes [27]. Int. J. Environ. Res. Public Health 2010, 7                
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Figure 1. ROS-induced cellular inflammatory response and oxidative damage. Schematic 
representation of the multiple pathways by which the exposure to reactive oxygen species 
originated by tobacco combustion can induce cellular damage and inflammation. 
 
3. Tobacco Smoke Induces Inflammatory and Thrombotic Injury   
Components of cigarette smoke also contribute to a pro-atherosclerotic environment by triggering a 
complex pro-inflammatory response through the recruitment of leukocytes to the site of inflammation 
via  cytokine  signaling  (such  as  IL-1β
  and  TNF-α)  [28],  matrix  metalloproteinase  upregulation   
(e.g.,  MMP-1  and  MMP-9),  and  by  promoting  the  adhesion  and  binding  of  monocytes  to  the 
endothelial wall of blood vessels [29]. Inflammatory activation of endothelial cells (ECs) leads to an 
increased expression
 of selectins, VCAM-1, and intercellular adhesion molecule-1
 (ICAM-1) [30]. This 
promotes the adherence of monocytes to vessel walls. Elevated levels of white blood cells, primarily 
neutrophils  and  monocytes  are  observed  in  smokers  [31].  In  particular,  neutrophils  secrete  free 
radicals, elastase and collagenase [32] which are thought to contribute directly to EC injury as they add 
to the immune response.   
Despite the fact that smoking triggers significant pro-inflammatory activity and active smokers 
therefore, have significantly higher number of circulating white blood cells [33], they are generally 
more susceptible to viral and bacterial inflammatory neuropathologies than non-smokers [34]. This 
suggests that chronic smoking causes desensitization rather than a potentiation of the response to other Int. J. Environ. Res. Public Health 2010, 7                
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inflammatory stimuli and may undermine the ability of the host immune system to counteract viral and 
bacterial infection. Desensitization of the host immune response, in addition to the compromising 
effect on the BBB integrity, can facilitate the pathogenesis of neurological disorders such as bacterial 
and viral meningitis [35-38]. 
Smokers are also reported to be at increased risk for thrombosis. Platelet activation is frequently 
observed in smokers in response to increased levels of platelet activating factor, Von Willebrand factor, 
catecholamines, and thromboxane. This phenomenon has been confirmed in vitro [39] and in vivo [40]. 
All  these  factors  pose a  serious  threat at  the level  of brain  microvasculature where vascular tone 
regulatory  mechanisms  are  absent.  Elevated  C-reactive  protein  (CRP)  levels  caused  by  cigarette 
smoking, can also promote endothelial dysfunction by lowering the production of nitric oxide (NO) 
and diminishing its bioactivity [41]. Recent studies demonstrated that CRP can decrease eNOS mRNA, 
augment  ET-1,  and  upregulate  nuclear  factor  B  (F-)  signaling  in  ECs  while  attenuating 
endothelial progenitor cell survival and differentiation.   
4. Pathophysiology of BBB Endothelial Cells 
The BBB has been shown to maintain brain homeostasis. It selectively excludes most endogenous 
and  xenobiotic  blood-borne  substances  from  entering  the  brain,  protecting  it  from  systemic  and 
exogenous  influences  [42-45].  The  BBB  dynamically  responds  to  hemodynamic  disturbances   
(e.g., focal ischemia), through free radical release and cytokine generation. It also plays a crucial role 
in  protecting  against  neurotoxicity.  Dysfunction  of  the  BBB  is  involved  in  the  pathogenesis  and 
progression of a number of neurological disorders (including stroke, multiple sclerosis, Alzheimer’s 
disease,  dementia,  epilepsy,  etc.)  [46].  Any  disorder  affecting  BBB  function  may  have  secondary 
effects on cerebral blood flow and vascular tone, further influencing transport across the microvascular 
endothelium. For example, cigarette smoke has been shown to lead to cerebrovascular vasodilation 
through  sympathetic  activation.  Nicotine  activates  nicotine  receptors,  which  leads  to  the   
acetylcoline-dependent release of NO from the vascular endothelium [47,48] through activation of 
endothelial nitric oxide synthase (eNOS) [49]. NO is one of the major endothelium-derived relaxing 
factors, which plays an active role in regulating microvascular tone and the cerebral blood flow under 
normal  and  pathological  conditions  [50].  Furthermore,  NO  has  been  shown  to  increase  vascular 
permeability at the BBB thus impairing brain homeostasis and facilitating the passage of unwanted 
substances from the blood into the brain [49,51,52]. 
Trans-endothelial leukocyte migration across an altered BBB is one of the most prominent features 
of many neuroimmune disorders; leukocytes are found in large numbers in the brain following trauma 
and certain neurodegenerative diseases. It is not clear whether the cells cross the endothelium through 
tight junctions, via a large pore or vacuole in the EC, or through some other mechanism [53]. The 
passage of cells across the BBB occurs when several cell types (blood cells and endothelial and/or glia) 
are activated [54]. Vascular EC at the site of inflammation undergo a number of morphologic and 
functional alterations, including increased permeability, hypertrophy, the accumulation of intracellular 
organelles, and proliferation [55].   
Exposure of endothelium to pro-inflammatory cytokines (TNF-α and IL-1β) interrupts the BBB by 
disorganizing  cell-cell  junctions,  decreasing  the  brain  solute  barrier  and  enhancing  leukocyte Int. J. Environ. Res. Public Health 2010, 7                
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endothelial adhesion and migration. Despite the crucial importance of the BBB and the strong scientific 
and clinical evidence for an association between TS exposure and vascular impairment, the effects of 
smoking on the BBB have been only marginally addressed and studies have been limited to a handful 
of substances among the multitudes found in cigarette smoke. 
5. Vascular and Inflammatory Effects of Tobacco Smoke on the BBB   
Tobacco smoke contains over 4 thousand chemicals (over 4 dozens of them are well established 
carcinogens). Direct and second hand exposure to tobacco smoke are associated with a number of 
physiological vascular changes that can lead to the pathogenesis of cerebrovascular-related diseases. 
For example, nicotine contained in tobacco smoke has been shown to negatively effect endothelial 
tight junctions [56] and the brain-to-blood Na
+ K
+ 2Cl
− co-transporter located on the luminal surface of 
BBB [57] (Figure 2).   
Figure 2. Exposure to nicotine impairs BBB function. Nicotine decreases expression of 
ZO1, which is a critical component of a variety of tight junctional proteins and that of the 
Na,  K,  2C  co-transporter.  This  can  lead  to  impaired  BBB  function  and  altered   
brain homeostasis.   
 
 
Increased blood viscosity, related to TS, can lead to impairment of blood flow, risking the integrity 
of  the  brain  microvasculature,  particularly  if  the  inter-endothelial  tight  junctions  are  already 
compromised.  Increased  levels  of  matrix-degrading  and  proinflammatory  changes  in  vascular  EC 
exposed to cigarette smoke have been found [29,58]. Int. J. Environ. Res. Public Health 2010, 7                
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In  addition  to  Nicotine,  which  has  been  proven  to  be  potentially  harmful  to  the  integrity  and 
function of the BBB [56,57,59-61], ROS promotes low-density lipoprotein oxidation which at the 
vascular level can cause cell injury and formation of atherosclerotic lesions [9,62]. At the BBB level 
ROS may induce pinocytosis, thus increasing transcytotic activity across the BBB endothelium [8] but 
can  also  cause  direct  BBB  breakdown  (especially  in  conditions  like  stroke  and  traumatic  brain   
injury [63]). This occurs by tight junction (TJ) modification, local matrix metalloproteinases (MMPs) 
activation  and  basal  membrane  degradation  [63].  ROS  and  nicotine  act  synergistically  with  other 
potentially harmful systemic stimuli (e.g., hypoperfusion of the brain vessels) to further impair both 
BBB function and integrity and leads to secondary brain damage. This hypothesis is supported by 
previous  studies  by  Yin  et  al.,  [64]  and  by  our  recently  published  data  demonstrating  that  BBB 
impairment associated with a transient loss of flow is significantly worsened by TS exposure [58]. 
Furthermore, in BBB endothelial cells TS exposure induced a significant transcriptional upregulation 
of  genes  involved  in  the  inflammatory  response.  Chemokines  (CCL2,  CXCL1,  CCL5,  etc.),   
pro-inflammatory  cytokines  (IL-8  IL-1β,  etc.),  STAT3,  (which  is  an  essential  regulator  of  the   
anti-inflammatory function of ECs in systemic immunity [65,66]), and other genes involved in the 
modulation of the endothelial inflammatory response to TS where all significantly upregulated [58]. In 
summary  smoking  and  hemodynamic  impairments  can  synergistically  contribute  to  vascular 
inflammation and BBB damage. 
Cigarette smoke contains high concentrations of NO [67], which may affect the viability of the 
BBB. Nitric oxide is a critical factor that affects the vascular tone, modulates platelet aggregation and 
leukocyte adhesion to the  endothelium. At the BBB, NO  plays  an inhibitory role in  the dynamic 
regulation  of  BBB  function  [68,69]  and  is  involved  in  a  variety  of  physiologic  and  pathological 
processes  as  part  of  the  inflammation  process  itself.  Early  during  ischemic  injury,  NO  has  a 
vasodilatatory  effect,  mediated  by  endothelial  nitric  oxide  synthase  (eNOS),  which  seems  to  be 
protective for the brain [70]. This is followed by massive production of inducible NO (iNOS), which 
peaks at 12–48 h after ischemia and occurs in inflammatory cells infiltrating the brain and in the 
cerebral  blood  vessels.  Through  a  process  of  redox  cycling  that  diverts  NO
 toward  peroxynitrite 
formation  nitric  oxide  is  inactivated  and  used  for  the  production  of  the  superoxide  anion  radical   
O2
− [7]. This is a highly reactive oxygen species that propagates inflammation to adjacent districts and 
extend the damage. In addition to NO systemically introduced by smoking, TS can also modulate the 
level NO by decreasing the activity of eNOS and promoting that of its inducible form (iNOS) [71]. 
The result is the initiation and progression of vasculo-pathogenic diseases such as atherosclerosis, 
thrombosis and ischemic like insults. 
6. Consequences of TS Induced Damage 
One mechanism by which smoking can harm health is directly related to hampered BBB viability 
and  function.  This  facilitates  the  pathogenesis  and  progression  of  a  number  of  neurological   
disorders [46,72,73]. There is indeed a correlation between smoking with an increased risk for multiple 
sclerosis [74], Alzheimer’s disease [75], and neurodevelopmental damage during pregnancy [76,77]. 
Small vessel ischemic disease: Chronic smokers have a higher incidence of small vessel ischemic 
disease (SVID) than non-smokers [58]. SVID is a pathological condition characterized by leaky brain Int. J. Environ. Res. Public Health 2010, 7                
 
4117 
microvessels and loss of BBB integrity. As part of an independent study started over a year ago by 
Cucullo et al., serum measurement of S100β, a marker of BBB integrity [72-74], has clearly shown a 
significantly higher degree of BBB disruption in smokers than non-smokers. This finding was further 
corroborated by Magnetic Resonance Imaging (MRI) scans showing widespread white and grey matter 
signals consistent with impaired BBB function [58], and by the presence of leaky microvessels. The 
study  revealed  that  smokers  have  a  significantly  higher  propensity  (83%  of  the  patients)  for 
cerebrovascular changes that lead to gadolinium enhancement and/or positive flair signals in the brain 
than non-smokers (36% of the patients).   
Cerebrovascular injuries: Cigarette smoking increases
 stroke incidence and brain infarction by 
approximately 50% [75,76] with a risk that raises proportionally with the amount of exposure whether 
derived from direct [77] or second hand smoking [78]. The increased stroke risk caused by smoking 
has been attributed to
 both pro-coagulant and atherogenic effects [79,80]. In particular it has been 
shown  that  TS  causes  a  dose  dependent  oxidant-mediated  stress  responses,  cell  death  in 
vascular
 endothelial  cells,  and  circulating  monocytes  which  are  the  major  cellular  player  in  the 
induction of atherosclerotic lesions [81]. A substantial relationship has been established between TS 
exposure  and  the  onset  of  silent  cerebral  infarction  (SCI)  that  is  comparable  with  that  of  known 
cerebrovascular risk factors such as hypertension [82]. SCI is a known cause for progressive brain 
damage resulting in vascular
 dementia.   
A recent study by Hossain et al. suggests that an ischemic-like event is likely to induce a stronger 
inflammatory response in smokers than non-smokers [58]. Relevant to the secondary post-ischemic 
brain injuries (and therefore, to the pathogenesis of many neurological and neurodegenerative diseases) 
is  the  pro-inflammatory  stimulus  of  TS  (increased  levels  of  IL-6,  TNF-α,  IL-1β  and  other   
pro-inflammatory  cytokines)  [83]  to  which  the  BBB  dynamically  responds.  This  facilitates  the 
pathogenesis and progression of a number of neurological disorders [45,84,85].   
Behavioral  impairment  and  increased  risk  for  sudden  infant  death  syndrome:  The  brain 
serotonin (5-HT) system has been demonstrated to play a major role in central nervous system (CNS) 
development, cognitive (memory and learning), and personality and behavioral modulatory processes. 
In fact, several neuropsychiatric conditions (e.g., obsessive compulsive disorder, anxiety, depression, 
schizophrenia, etc.) as well as impaired brain functions (e.g., sleep disorders, appetite, etc.) have been 
related to an altered serotonin (5-HT) system. Recent studies in pregnant Rhesus monkeys exposed to 
environmental  tobacco  smoke  have  clearly  shown  specific  (5-HT)  receptor  deregulation  in  the 
developing neonates and suggest that this may be responsible for behavioral abnormalities associated 
with perinatal tobacco exposure [86]. Furthermore, recent studies have clearly shown a link between 
impaired BBB function with the onset of depression and schizophrenia [87].   
According to studies by Teaktong et al., acute inhibition of serotonin neurons, which control a wide 
range of behavioral and physiological processes, is primarily related to an effect on nicotine receptors 
[88,89]. Prenatal and early postnatal exposure to tobacco smoke has also been associated with an 
increased risk for sudden infant death syndrome (SIDS). Experiments performed in pregnant monkeys 
suggest that the effect of tobacco smoke exposure on SIDS may be mediated by respiratory problems 
associated to neuroplastic changes in the nucleus of the solitary tract (NTS) [90] where lung sensory 
information and respiratory function are first integrated. Furthermore, recent studies have shown an Int. J. Environ. Res. Public Health 2010, 7                
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increased expression of active caspase-3 (a marker of cell apoptosis) in the brainstem of SIDS infants 
who have been exposed to passive smoke [91]. 
7. New Tobacco Products: Lower Risks or More of the Same? 
Besides elevating the risk of at least nine forms of cancer [92], smoking is linked to heart disease, 
emphysema, and pulmonary disorders.   
The issuance of the NCI’s Monograph 13 on “light” and “low tar” cigarettes demonstrates the 
problem  of  relying  on  tobacco  industry  claims  of  reduced  risk  for  its  products  in  the  absence  of 
meaningful government regulation and oversight. Light and low tar cigarettes were introduced with 
claims of a reduction in harmful components and implied health benefits. Decades later and after 
millions of health concerned consumers switched to these products, the evidence demonstrates that 
these expectations were false. Today the tobacco industry is introducing a whole new line of products 
with claims and representations that are stunningly similar to those made for light and low tar products 
when they were introduced. However, in the absence of government regulation of these products and 
claims, the American public has no greater certainty that the claims being made for these new products 
are any more reliable than the claims made for light and low tar cigarettes.   
OMNI and Advance are two examples of so-called “reduced risk cigarettes” or “potential reduced 
exposure products” (PREPs) that have recently become available in the stores in the United States. 
Advance  cigarettes  are  made  with  a  special  tobacco-curing  process  and  a  filter  that  reduce 
nitrosamines  and  hydrocarbons.  Omni  also  uses  tobacco  processed  to  reduce  nitrosamines  and 
hydrocarbons. Both products have been marketed as less dangerous alternatives to smoking traditional 
cigarettes. Smokeless or non-combusted oral tobacco products are also gaining greater momentum and 
interest by both the public health community and the tobacco industry. These products (such as Revel 
manufactured by the U.S. Smokeless Tobacco Company; USSTC and Camel Snus manufactured by 
Swedish Match) were introduced as a “safe” replacement for cigarette smoking.   
In both cases the claim of “decreased risk” is dubious because: (1) there is no proof that reducing 
hydrocarbons  or  nitrosamines  translates  to  a  decreased  risk  to  smokers;  (2)  although  the  overall 
exposure to potentially harmful substances generated during cigarette combustion is lower with PREPs 
than with regular cigarettes, addiction to tobacco use is not reduced [93]; (3). Despite the fact that 
PREPs  may  not  expose  the  user  to  some  of  the  potentially  noxious  compounds  associated  with 
combustion,  they  still  contain  over  2  dozens  carcinogens  including  N’-nitrosonornicotine  (NNN) 
formed during the curing, processing, and aging of tobacco [94,95]; (4). With up to 4,000 chemicals 
present in cigarette smoke, the risks to smokers are varied and many still unidentified. Therefore it is 
impossible at the current stage to affirm that PREPs are a safe replacement for conventional tobacco 
products. This is a remarkable public health issue because smokers may be misled into assuming that 
smokeless and reduced-exposure tobacco products are actually safe.   
Oral nicotine and non-combusted reduced exposure equivalents seem to have higher potential to 
reduce harm than cigarettes manufactured by altering tobacco and tobacco curing processes because of 
the  lack  of  combustion  byproducts  (Figure  3).  However,  their  impact  on  public  health  is  highly 
dependent  on  marketing  and  public  acceptance.  Furthermore,  the  level  of  exposure  to  potentially 
harmful  substances  including  many  acknowledged  carcinogens  is  still  elevated.  In  this  midst  of Int. J. Environ. Res. Public Health 2010, 7                
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uncertainties, further studies are also needed to assess how the relative importance of BBB and CNS 
effects might have shifted with these alternative tobacco products.   
Figure 3. Cigarette products and harm potential. General overview of currently available 
“harm reduction” and smokeless cigarette products.   
 
8. Conclusions   
In summary, while the harmful effects of smoking on public health have been well demonstrated the 
underlying  mechanisms  of  toxicity  are  not  fully  understood.  At  the  cerebrovascular  level  and 
specifically  at  the  BBB  cigarette  smoking  can  severely  impair  endothelial  physiology  by  directly 
affecting endothelial tight junctions [56,58] and the ionic homeostasis across the endothelium [57]. 
The exposure to highly reactive oxygen species generated by cigarette combustion can cause oxidative 
damage [6,11] and trigger a strong inflammatory cascade that can lead to the onset and/or facilitate the 
progression of many CNS disorders [45,84,85,96-98].   Int. J. Environ. Res. Public Health 2010, 7                
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To date, the scientific evidence is insufficient to evaluate whether PREPs reduce the users’ risk for 
tobacco-related diseases. Additional independent studies aimed at assessing the potential toxicity of 
these new products are necessary. 
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